{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:06:50Z","timestamp":1770494810396,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.urolonc.2024.01.030","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T19:18:30Z","timestamp":1708456710000},"page":"119.e17-119.e22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Natural history of bone-only metastasis in renal cell carcinoma"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3458-461X","authenticated-orcid":false,"given":"Bixia","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huayan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caili","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-0975","authenticated-orcid":false,"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.01.030_bib0001","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100399","article-title":"All bone metastases are not created equal: revisiting treatment resistance in renal cell carcinoma","volume":"31","author":"Brozovich","year":"2021","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0003","doi-asserted-by":"crossref","first-page":"e83026","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey","volume":"8","author":"Santini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0004","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0005","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/j.clgc.2016.12.005","article-title":"Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER\u2013Medicare database analysis","volume":"15","author":"Pal","year":"2017","journal-title":"Clin Genitourinary Cancer"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0006","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0007","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.10.023","article-title":"Prognosis of renal cell carcinoma with bone metastases: experience from a large cancer centre","volume":"107","author":"Ruatta","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0008","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0009","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO Guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41585-018-0034-9","article-title":"An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma","volume":"15","author":"Gr\u00fcnwald","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0011","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1016\/j.clgc.2017.10.012","article-title":"Bone metastases as the only metastatic site in patients with urothelial carcinoma: focus on a special patient population","volume":"16","author":"Necchi","year":"2018","journal-title":"Clin Genitourinary Cancer"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0012","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2006.10.060","article-title":"Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone","volume":"52","author":"Toyoda","year":"2007","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.01.030_bib0013","article-title":"First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis","volume":"5","author":"Aldin","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0014","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0015","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3389\/fonc.2019.01400","article-title":"Biomarkers of prognosis and efficacy of anti-angiogenic therapy in metastatic clear cell renal cancer","volume":"9","author":"D'Aniello","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0016","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1200\/JCO.2020.38.6_suppl.655","article-title":"Does presence of bone metastases portend worsened prognosis in metastatic renal cell carcinoma? Analysis of the REMARCC (Registry of MetAstatic RCC) database","volume":"38","author":"Bradshaw","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0017","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0019","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2022.40.6_suppl.342","article-title":"Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study","volume":"40","author":"Velev","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2024.01.030_bib0020","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T03:46:49Z","timestamp":1730864809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1078143924000450"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.030","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural history of bone-only metastasis in renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}